

RELEVANT FACT

Grifols S.A.

Grifols hereby informs that today it has agreed a long term loan for 100 million euros with the European Investment Bank (EIB), under the new European Fund for Strategic Investments (EFISI).

The loan will be used to support its investment in R&D, focusing primarily on the search for new indications for plasma proteins, including the treatment of Alzheimer's disease, vascular diseases, cardiovascular surgery and arterial thrombosis, amongst others.

The financial conditions include a fixed interest rate for a tenor of ten years with a grace period of two years.

Grifols is one of the first European companies to receive a loan from the EFISI, also known as the Juncker Plan.

In Barcelona, on 28 October 2015

Núria Martín Barnes
Secretary to the Board of Directors